Therma Bright Inc V.THRM

THRM sensitivity of 86% and specificity of 100% vs Abbott

[KILOFINAL]

Abbott's Panbio rapid antigen test had a sensitivity of 74.4% and specificity of 99.9% in a Norway study. Therma Bright's numbers are excellent 

https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbots%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-3ca5a99f5367:10fe6f072721ece7aeeb30fb46eb3259e5a8decc/Evaluation%20of%20Abbots%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf

Summary The Abbott PanbioTM COVID-19 Ag Rapid Test Device (Panbio rapid antigen test (RAT)) was compared to inhouse SARS-CoV-2 PCR in an evaluation performed on 3991 samples from a test station in Oslo and 866 samples from outbreaks in Norway in the period October 30th to November 25th 2020. 250 samples (6.3 %) were positive at Aker test station and 60 (6.9 %) at the outbreaks all together. At Aker test station the over-all sensitivity was 74.4 % and the specificity was 99.9 %, compared to the PCR results from Oslo University Hospital. Positive and negative predictive values were 0.984 and 0.983, respectively, showing high accuracy of both positive and negative test results at the given prevalence (6,3%) at the time. In the outbreak material, the sensitivity was 70 %, and the specificity was 100 %. Due to the lower sensitivity of the Panbio RAT, we conclude that for diagnosing serious illness and hospitalized patients, PCR remains the preferred method. However, RATs have been launched for other purposes: Epidemiological surveillance and contact tracing. A lower sensitivity can be tolerated in this context and compensated for by higher availability, higher turnaround time and repeated testing. The Panbio RAT had a lower detection limit corresponding approximately to 1.4 million copies/mL. Studies have shown that clinical samples with less than 1 million copies/mL are unlikely to cultivate in the laboratory and thus also less likely to be infectious from one person to another. In the Aker test station material, the sensitivity of the Panbio RAT was 83.8 % for samples with a viral load above this limit, indicating that the majority of infectious individuals will be detected with the test. For patients symptomatic for less than five days, the sensitivity was 79.8 %. These sensitivity figures are within WHO’s guidelines for RATs used in surveillance. For subjects without symptoms, the sensitivity was only 55.3 %, showing that the Panbio RAT is best suited for use in symptomatic patients, and that PCR will be a necessary backup method if RATs are used in this group. Due to the lower sensitivity of the Panbio RAT, guidelines for correct use are important. Correct use of RATs will for example be highly influenced by the actual disease prevalence. RATs may prove to be valuable tools in controlling the COVID-19 pandemi

[NMINML]

Is this the one that's currently being used in the US? I read they did em at the last couple Bills games but can't remember if that was an Abbott test or not. Sounds like little Therma is gunning to be the best in the world! 

[nrv090909]

My thoughts are is therma is being set up for a major buyout from a Health care company (who already has manufacturing, distribution and money). Johnson and Johnson was my day 1 prediction. 1 J&J share for every 20 Therma Shares. 

[cote101]

YESSSS i will take it anytime, share of J&J are at 160$ US dollars my friend Cote101